基于网络药理学探究参苓白术丸改善肌少症的关键活性成分OA

This study aims to explore the key active components of Shenling Baizhu Pill(SLBZP)in treating sarcopenia.The study utilizes Ultra-performance Liquid Chromatography/Quadrupole Time-of-flight Mass Spectrometry(UPLC-Q/TOF-MS)to analyze the chemical components in the extract of SLBZP;combines network pharmacology to predict the effective components and poten-tial core targets of SLBZP to improve sarcopenia;and employs a dexamethasone-induced zebrafish sarcopenia model to evaluate the sarcopenia-improving activity of SLBZP.Reverse Transcription-polymerase Chain Reaction(RT-PCR)is used to detect the expres-sion of related genes.The results show that 87 compounds were detected in the extract of SLBZP;network pharmacology analysis reveals that five potential active components in SLBZP,including genistein,diosgenin III,diosgenin IV,naringenin,and kaempferol,primarily act on targets such as AKT serine/threonine kinase 1(AKT,AKT1),interleukin-6(IL-6),F-Box Protein 32(FBXO32),and Tripartite Motif Containing 63(TRIM63).Molecular docking indicates that naringenin has a high binding affinity with FBXO32 pro-tein,and molecular dynamics simulations further reveal that the naringenin-FBXO32 complex exhibits good stability.Animal experi-ments on zebrafish demonstrate that naringenin significantly enhances the locomotor ability of the sarcopenia zebrafish model,im-proves muscle density in the model animals,and downregulates the mRNA expression of FBXO32 and TRIM63.In summary,this study is the first discovery to identify naringenin in Shenling Baizhu Pill as a potential key pharmacodynamic component for improv-ing sarcopenia,providing a theoretical basis for revealing the improve sarcopenia active components and mechanisms of action of SLBZP.